Davis Matthew W., the Chief Development Officer at Aquestive Therapeutics, Inc., recently reported a stock transaction that involves the sale of shares. This event is significant as it provides insight into the financial activities of key executives within the company.

Aquestive Therapeutics, based in Warren, New Jersey, operates in the pharmaceutical preparations industry. The company is known for its innovative approaches to drug delivery and development. According to the latest filings, Davis has been actively involved in the company’s strategic initiatives.

The filing, accession number 0001214659-26-014000, indicates that on November 10, 2026, Davis sold 5,303 shares of common stock at a price of $3.52 per share. Following this transaction, he retains ownership of 94,697 shares. The filing specifies that this sale was made to satisfy tax withholding obligations related to the vesting of certain Restricted Stock Units (RSUs) previously granted to him.

This transaction may impact investor perception, as executive stock sales can sometimes raise questions about the company's future prospects. However, it is important to note that such transactions are often routine and part of personal financial planning.

As for what’s next, the filing does not specify any upcoming actions or further disclosures related to this transaction.

Details of the Transaction

The transaction reported by Davis Matthew W. was classified under transaction code 'F', indicating that it was a disposition of securities. The shares sold were withheld by the issuer, Aquestive Therapeutics, to meet tax obligations arising from the vesting of Restricted Stock Units (RSUs). This is a common practice among executives to manage tax liabilities associated with equity compensation.

Company Background

Aquestive Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector, specifically focusing on innovative drug delivery systems. The company is classified under the Standard Industrial Classification (SIC) code 2834. As of the latest information, the company's fiscal year ends on December 31, and it has a Central Index Key (CIK) of 0001398733.

Reporting Owner Information

Davis Matthew W. serves as the Chief Development Officer of the company, and his reporting owner ID is associated with the CIK number 0002094283. His address for filings is listed as C/O Aquestive Therapeutics, 184 Liberty Corner Drive, Suite 305, Warren, NJ 07059.

This filing does not provide any additional insights into the company's future plans, financial performance, or other executive transactions that may have occurred around the same time.